A K Larsen
Overview
Explore the profile of A K Larsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Larsen A, Escargueil A, Skladanowski A
Pharmacol Ther
. 2000 Mar;
85(3):217-29.
PMID: 10739876
The resistance of tumor cells to anticancer agents remains a major cause of treatment failure in cancer patients. The term multidrug resistance (MDR) is used to define a resistance phenotype...
12.
Scala D, Escargueil A, Couprie J, Larsen A
Biochimie
. 1999 Sep;
81(7):771-9.
PMID: 10492025
DNA topoisomerase II regulates the three-dimensional organisation of DNA and is the principal target of many important anticancer and antimicrobial agents. These drugs usually act on the DNA cleavage/religation steps...
13.
Larsen A, Gobert C
Pathol Oncol Res
. 1999 Sep;
5(3):171-8.
PMID: 10491013
Mammalian DNA topoisomerase I is a multifunctional enzyme which is essential for embryonal development. In addition to its classical DNA nicking-closing activities which are needed for relaxation of supercoiled DNA,...
14.
Gobert C, Skladanowski A, Larsen A
Proc Natl Acad Sci U S A
. 1999 Sep;
96(18):10355-60.
PMID: 10468612
DNA topoisomerase I is a nuclear enzyme involved in transcription, recombination, and DNA damage recognition. Previous studies have shown that topoisomerase I interacts directly with the tumor-suppressor protein p53. p53...
15.
Come M, Bettaieb A, Skladanowski A, Larsen A, Laurent G
Int J Cancer
. 1999 May;
81(4):580-7.
PMID: 10225448
We have previously shown that in myeloid leukemic cells, daunorubicin (DNR) induces apoptosis via the activation of the sphingomyelin-ceramide pathway. We have now investigated sphingomyelin (SM) hydrolysis, ceramide generation, and...
16.
Come M, Skladanowski A, Larsen A, Laurent G
Br J Cancer
. 1999 Mar;
79(7-8):1090-7.
PMID: 10098741
Exposure of some acute myeloid leukaemia (AML) cells to daunorubicin leads to rapid cell death, whereas other AML cells show natural drug resistance. This has been attributed to expression of...
17.
Larsen A, Gobert C, Gilbert C, Markovits J, Bojanowski K, Skladanowski A
Acta Biochim Pol
. 1998 Nov;
45(2):535-44.
PMID: 9821882
DNA topoisomerases regulate the organization of DNA and are important targets for many clinically used antineoplastic agents. In addition, DNA topoisomerases modulate the cellular sensitivity toward a number of DNA...
18.
Larsen A, Skladanowski A
Biochim Biophys Acta
. 1998 Sep;
1400(1-3):257-74.
PMID: 9748618
DNA topoisomerase inhibitors are important antineoplastic agents used in the treatment of both leukemias and solid tumors, such as breast, lung and colon cancers. Their clinical usefulness is limited by...
19.
Vitrat N, Pique C, Le Couedic J, Norol F, Larsen A, Katz A, et al.
Blood
. 1998 Jun;
91(10):3711-23.
PMID: 9573008
During megakaryocyte differentiation, the promegakaryoblast (immature megakaryocyte) increases its ploidy to a 2(x) DNA content by a poorly understood process called endomitosis. This leads to the formation of a giant...
20.
Robert J, Larsen A
Biochimie
. 1998 Jun;
80(3):247-54.
PMID: 9615864
We describe in this review the mechanisms of resistance to topoisomerase II inhibitors that have been identified in cell lines rendered resistant to drugs. They concern especially both quantitative and...